A detailed history of Black Rock Inc. transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,283,324 shares of MORF stock, worth $110 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,283,324
Previous 3,302,686 0.59%
Holding current value
$110 Million
Previous $95.4 Million 21.17%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$26.64 - $40.31 $515,803 - $780,482
-19,362 Reduced 0.59%
3,283,324 $116 Million
Q4 2023

Feb 13, 2024

BUY
$19.95 - $31.0 $8.29 Million - $12.9 Million
415,594 Added 14.39%
3,302,686 $95.4 Million
Q3 2023

Nov 13, 2023

BUY
$21.33 - $59.42 $2.95 Million - $8.22 Million
138,274 Added 5.03%
2,887,092 $66.1 Million
Q2 2023

Aug 11, 2023

BUY
$34.33 - $62.11 $16.8 Million - $30.4 Million
488,849 Added 21.63%
2,748,818 $158 Million
Q1 2023

May 12, 2023

BUY
$26.01 - $48.69 $4.4 Million - $8.23 Million
169,044 Added 8.08%
2,259,969 $85.1 Million
Q4 2022

Feb 13, 2023

BUY
$24.14 - $30.37 $3.49 Million - $4.39 Million
144,628 Added 7.43%
2,090,925 $55.9 Million
Q3 2022

Nov 14, 2022

BUY
$22.23 - $33.37 $743,348 - $1.12 Million
33,439 Added 1.75%
1,946,297 $55.1 Million
Q2 2022

Aug 12, 2022

BUY
$19.74 - $43.01 $1.85 Million - $4.02 Million
93,489 Added 5.14%
1,912,858 $41.5 Million
Q1 2022

May 12, 2022

BUY
$36.25 - $52.02 $588,192 - $844,076
16,226 Added 0.9%
1,819,369 $73 Million
Q4 2021

Feb 10, 2022

BUY
$43.27 - $65.72 $9.22 Million - $14 Million
213,051 Added 13.4%
1,803,143 $85.4 Million
Q3 2021

Nov 09, 2021

BUY
$53.61 - $67.5 $7.33 Million - $9.23 Million
136,795 Added 9.41%
1,590,092 $90.1 Million
Q2 2021

Aug 11, 2021

BUY
$45.13 - $64.99 $65.6 Million - $94.4 Million
1,453,297 New
1,453,297 $83.4 Million

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $1.29B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.